Food and Drug Regulations, C.R.C., c. 870
Section C.10.007.1
Cite as Food and Drug Regulations, C.R.C., c. 870, s. C.10.007.1 · current to June 17, 2026 · regulation last amended June 17, 2026
Statute Watch
Get an alert when a bill in Parliament would change this section, and every time it moves.
The text
(1) Despite sections C.01.003, C.01.014 and C.08.002 and subject to subsections (3), (4) and (6), a person who holds an establishment licence may sell a designated drug that is set out in Part 2 of the List of Drugs for Exceptional Importation and Sale for consumption or use in Canada if the conditions set out in subsection (2) are met and, as the case may be,
(a) they are the distributor of the drug for consumption or use outside Canada; or
(b) they are a wholesaler of a drug.
(2) The conditions are the following:
(a) the licensee provides the Minister, in the form and manner specified by the Minister and not later than three business days before the day on which the licensee first sells the designated drug for consumption or use in Canada, with a notification that contains the following information:
(i) the licensee’s name and contact information,
(ii) the name and contact information of each fabricator, packager/labeller and tester of the drug and the address of each building in which it is fabricated, packaged/labelled or tested, and
(iii) in respect of the drug,
(A) its brand name,
(B) its medicinal ingredients,
(C) its dosage form,
(D) its strength,
(E) its route of administration,
(F) its identifying code or number, if any, assigned in the country in which it is authorized for sale, and
(G) a detailed description of its conditions of use;
(b) if the licensee meets the condition set out in paragraph (1)(b) and the designated drug is referred to in any of paragraphs (a), (c) or (d) of the definition wholesaler in subsection C.01A.001(1), the drug is in the same category as the category for which the establishment licence was issued;
(c) the following information in respect of the designated drug is set out in Part 2 of the List of Drugs for Exceptional Importation and Sale:
(i) the licensee’s name,
(ii) the information referred to in clauses (a)(iii)(A) to (F),
(iii) the name of the foreign regulatory authority referred to in clause C.10.005(2)(b)(ii)(B),
(iv) the maximum limit on the total quantity of the drug that the licensee may sell, if applicable,
(v) the date after which the licensee is no longer permitted to sell the drug, if applicable, and
(vi) the lot or batch number of the drug;
(d) the licensee ensures that the information referred to in clause (a)(iii)(G) is available in English and French and in a manner that permits the safe use of the designated drug; and
(e) the licensee has prepared a plan that specifies the measures to be taken in order for them to comply with paragraph (d).
(3) The licensee shall not sell, in total, the designated drug in a quantity that exceeds the maximum limit referred to in subparagraph (2)(c)(iv), if applicable.
(4) The licensee shall not sell the designated drug after the date referred to in subparagraph (2)(c)(v), if applicable.
(5) The licensee shall ensure that the information referred to in clause (2)(a)(iii)(G) is available in accordance with paragraph (2)(d) until at least the latest expiration date of the designated drug that they sold.
(6) This section does not apply — in respect of a designated drug sold by the licensee under subsection (1) — to another person who holds an establishment licence and sells the drug.
Read the Food and Drug Regulations on the Justice Laws Website ↗
Made under Food and Drugs Act, R.S.C. 1985, c. F-27.
Bills in Parliament that would change this section 0
No bill we hold would amend or repeal this section.